Vivos Therapeutics (VVOS) Asset Writedowns and Impairment (2023)
Vivos Therapeutics' (VVOS) quarterly Asset Writedowns and Impairment came in at $151000.0 in Q3 2023.
Vivos Therapeutics (VVOS) Asset Writedowns and Impairment (2023) Analysis & Trends
Vivos Therapeutics (VVOS) has 1 years of Asset Writedowns and Impairment data on file, last reported at $151000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.51 Bn | 174.22 Bn | 6.27 Bn |
| 2 | Stryker | 128.20 Bn | 125.32 Bn | 3.81 Bn |
| 3 | Medtronic | 107.69 Bn | 98.47 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.05 Bn | 66.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.52 Bn | 43.85 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.46 Bn | 26.17 Bn | 1.98 Bn |
| 7 | Dexcom | 28.25 Bn | 27.13 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 26.73 Bn | 26.15 Bn | - |
| 9 | Koninklijke Philips | 25.31 Bn | 22.19 Bn | 2.07 Bn |
| 10 | Vivos Therapeutics | 6.01 Mn | 3.90 Mn | 3.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 151,000.00 |
| Sep 30, 2023 | 151,000.00 |